Baxter/Halozyme Hyaluronidase Enhanze SC Could See Approval By September
This article was originally published in The Pink Sheet Daily
Executive Summary
The firms are touting the hyaluronidase agent’s recombinant human origin as a key advantage over currently available animal-derived hyaluronidase products. Enhanze SC would be the third hyaluronidase on the market but the first that is human-derived.